



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Tahereh Tabatabaie and Yashige Kotake

Serial No.: 09/852,587

Filed: May 10, 2001

For: PREVENTION OF INSULIN-DEPENDENT DIABETES,

COMPLICATIONS THEREOF, OR ALLOGRAFT REJECTION BY

INHIBITION OF CYCLOOXYGENASE-2

ACTIVITY

Group Art Unit: 1640

Examiner: Shahnman J. Sharareh

Atty. Dkt. No.: OMRF:008US/SLH

RESPONSE TO RESTRICTION REQUIREMENT DATED OCTOBER 3, 2003

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Commissioner:

This paper is submitted in response to the Restriction Requirement dated October 3, 2003 for which the date for response is November 3, 2003.

It is believed that no fee is due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to this document, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/OMRF:008US/SLH.

In response to the restriction requirement which the Examiner imposed, Applicants elect, without traverse, to prosecute claims 1-7, 10-13, 15-23, *i.e.*, the Group 1 claims.

The Examiner is invited to contact the undersigned attorneyat (512) 536-3184 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,

Steven 1). Highlander

Attorney for Applicants

Reg. No. 37,642

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 536-3184

Date:

11/3/03